Trial reportJournal of the Egyptian National Cancer Institute2025
A case-control study investigating the impact of gradient pressure therapy on chemotherapy-induced peripheral neuropathy symptoms and daily activities in paclitaxel-treated patients.
Trial report in Journal of the Egyptian National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposePaclitaxel chemotherapy is known to induce peripheral neuropathy, significantly impacting patients' daily activities. Effective interventions to alleviate these symptoms are crucial for improving patient quality of life. The objective was to investigate the effects of gradient pressure therapy on symptoms of paclitaxel-induced peripheral neuropathy and daily activities.
methodsEighty patients with breast cancer receiving a 125-mg/m
resultsNo significant differences were found in CIPN symptoms and ADL impact scores between the groups after the second chemotherapy cycle (P > 0.05). However, after the fourth cycle, the intervention group showed significant improvements in nine items: hand numbness, foot numbness, discomfort in fingers/hands or toes/feet, walking, exercise, sleep, sexual activity, chores, and enjoyment of life (P < 0.05). At the sixth cycle and at the 3-month follow-up, additional improvements were noted in cold sensitivity and total scores (P < 0.05).
conclusionGradient pressure therapy effectively reduces symptoms of paclitaxel-induced peripheral neuropathy, improving patients' daily activities. This intervention is recommended for clinical promotion and application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.